Cite
HARVARD Citation
Cummings, J. et al. (n.d.). P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study. Alzheimer's & dementia. p. P658. [Online].